Abatacept has demonstrated benefits in patients with RA and an inadequate response to methotrexate7 that are comparable to those observed in studies of TNF blockade, with efficacy also confirmed in the particularly resistant group of patients who have failed TNF blockade therapy.8 This evidence concerns the gene TNF and rheumatoid arthritis.